Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

Singh, 1999, Effects of food on clinical pharmacokinetics, Clin. Pharmacokinet., 37, 213, 10.2165/00003088-199937030-00003 Harris, 2003, Dietary effects on drug metabolism and transport, Clin. Pharmacokinet., 42, 1071, 10.2165/00003088-200342130-00001 Food and Drug Administration, 2002 Jones, 2006, Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modeling, Clin. Pharmacokinet., 45, 1213, 10.2165/00003088-200645120-00006 Lentz, 2007, Development and validation of a preclinical food effect model, J. Pharm. Sci., 96, 459, 10.1002/jps.20767 Wei, 2006, Biorelevant dissolution media as a predictive tool for glyburide a class II drug, Eur. J. Pharm. Sci., 29, 45, 10.1016/j.ejps.2006.05.004 Kataoka, 2006, Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system, J. Pharm. Sci., 95, 2051, 10.1002/jps.20691 Amidon, 1995, A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413, 10.1023/A:1016212804288 Food and Drug Administration, 2000 Wu, 2005, Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharm. Res., 22, 11, 10.1007/s11095-004-9004-4 Lennernas, 1997, Human jejunal effective permeability and its correlation with preclinical drug absorption models, J. Pharm. Pharmacol., 49, 627, 10.1111/j.2042-7158.1997.tb06084.x van de Waterbeemd, 1998, The fundamental variables of the biopharmaceutics classification system (BCS): a commentary, Eur. J. Pharm. Sci., 7, 1 Blume, 1999, The biopharmaceutics classification system (BCS): class III drugs—better candidates for BA/BE waiver?, Eur. J. Pharm. Sci., 9, 117, 10.1016/S0928-0987(99)00076-7 Fleisher, 1999, Drug, meal and formulation interactions influencing drug absorption after oral administration, clinical implications, Clin. Pharmacokinet., 36, 233, 10.2165/00003088-199936030-00004 Löbenberg, 2000, Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, Eur. J. Pharm. Biopharm., 50, 3, 10.1016/S0939-6411(00)00091-6 Avdeef, 2001, Physicochemical profiling (solubility, permeability and charge state), Curr. Top. Med. Chem., 1, 277, 10.2174/1568026013395100 Rege, 2001, Effect of common excipients on Caco-2 transport of low-permeability drugs, J. Pharm. Sci., 90, 1776, 10.1002/jps.1127 Tannergren, 2001, Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity, Pharmazie, 56, 337 Kanfer, 2002, Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice, J. Pharm. Pharm. Sci., 5, 1 Lennernas, 2002, The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique, Eur. J. Pharm. Sci., 15, 271, 10.1016/S0928-0987(02)00005-2 Martinez, 2002, A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals, J. Clin. Pharmacol., 42, 620, 10.1177/00970002042006005 Taub, 2002, Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I–IV, Eur. J. Pharm. Sci., 15, 331, 10.1016/S0928-0987(02)00015-5 Yu, 2002, Biopharmaceutics classification system: the scientific basis for biowaiver extensions, Pharm. Res., 19, 921, 10.1023/A:1016473601633 Bergström, 2003, Absorption classification of oral drugs based on molecular surface properties, J. Med. Chem., 46, 558, 10.1021/jm020986i Tannergren, 2003, The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique, Br. J. Clin. Pharmacol., 55, 182, 10.1046/j.1365-2125.2003.01722.x Lindenberg, 2004, Classification of orally administered drugs on the World Health Organization Model of Essential Medicines according to the biopharmaceutics classification system, Eur. J. Pharm. Biopharm., 58, 265, 10.1016/j.ejpb.2004.03.001 Jorgensen, 2002, Prediction of drug solubility from structure, Adv. Drug Deliv. Rev., 54, 355, 10.1016/S0169-409X(02)00008-X Bergström, 2005, In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption, Basic Clin. Pharmacol. Toxicol., 96, 156, 10.1111/j.1742-7843.2005.pto960303.x Bergström, 2005, Computational models to predict aqueous drug solubility, permeability and intestinal absorption, Expert Opin. Drug Metab. Toxicol., 1, 613, 10.1517/17425255.1.4.613 Amidon, 1988, Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds, Pharm. Res., 5, 651, 10.1023/A:1015927004752 Kunta, 2004, Intestinal drug transporters: in vivo function and clinical importance, Curr. Drug Met., 5, 109, 10.2174/1389200043489144 Fagerholm, 2007, Prediction of human pharmacokinetics — gastrointestinal absorption, J. Pharm. Pharmacol., 59, 905, 10.1211/jpp.59.7.0001 Paine, 1996, First-pass metabolism of midazolam by the human intestine, Clin. Pharmacol. Ther., 60, 14, 10.1016/S0009-9236(96)90162-9 DeSesso, 2001, Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats, Food Chem. Toxicol., 39, 209, 10.1016/S0278-6915(00)00136-8 Shitara, 2006, Transporters as a determinant of drug clearance and tissue distribution, Eur. J. Pharm. Sci., 27, 425, 10.1016/j.ejps.2005.12.003 Kim, 2005, Transporters and drug discovery: why, when, and how, Mol. Pharm., 3, 26, 10.1021/mp050084o Seithel, 2006, Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells, Eur. J. Pharm. Sci., 28, 291, 10.1016/j.ejps.2006.03.003 Englund, 2006, Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells, Eur. J. Pharm. Sci., 29, 269, 10.1016/j.ejps.2006.04.010 Kalantzi, 2006, Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies, Pharm. Res., 23, 165, 10.1007/s11095-005-8476-1 Brouwers, 2007, Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state, Pharm. Res., 24, 1862, 10.1007/s11095-007-9307-3 Welling, 1996, Effects of food on drug absorption, Annu. Rev. Nutr., 16, 383, 10.1146/annurev.nu.16.070196.002123 Galia, 1998, Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs, Pharm. Res., 15, 698, 10.1023/A:1011910801212 Dressman, 2000, In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs, Eur. J. Pharm. Sci., 11, S73, 10.1016/S0928-0987(00)00181-0 Leyden, 1985, Absorption of minocycline hydrochloride and tetracycline hydrochloride, effect of food, milk, and iron, J. Am. Acad. Dermatol., 12, 308, 10.1016/S0190-9622(85)80041-4 Carver, 1999, Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients, Pharm. Res., 16, 718, 10.1023/A:1018880726035 Liedholm, 1986, Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation, Clin. Pharmacol. Ther., 40, 29, 10.1038/clpt.1986.135 Ratain, 2007, The value meal: how to save $1,700 per month or more on lapatinib, J. Clin. Oncol., 25, 3397, 10.1200/JCO.2007.12.0758 Schmidt, 2002, Food–drug interactions, Drugs., 62, 1481, 10.2165/00003495-200262100-00005 Smith, 1994, Design of drugs through a consideration of drug metabolism and pharmacokinetics, Eur. J. Drug Metab. Pharmacokinet., 3, 193, 10.1007/BF03188921 Ito, 2005, Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport, Pharm. Res., 22, 1559, 10.1007/s11095-005-6810-2 Kim, 1998, The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors, J. Clin. Invest., 101, 289, 10.1172/JCI1269 Polli, 2001, Rational use of in vitro P-glycoprotein assays in drug discovery, J. Pharmacol. Exp. Ther., 299, 620 Taub, 2002, Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I–IV, Eur. J. Pharm. Sci., 15, 331, 10.1016/S0928-0987(02)00015-5 Lu, 1996, Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes, J. Pharm. Sci., 85, 270, 10.1021/js950269u Yee, 1997, In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man—fact or myth, Pharm. Res., 14, 763, 10.1023/A:1012102522787 Watanabe, 2002, Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2, Biol. Pharm. Bull., 25, 885, 10.1248/bpb.25.885 Watanabe, 2002, Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2, Biol. Pharm. Bull., 25, 1345, 10.1248/bpb.25.1345 Sun, 2002, Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs, Pharm. Res., 19, 1400, 10.1023/A:1020483911355 Bourdet, 2006, Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells, Pharm. Res., 23, 1178, 10.1007/s11095-006-0204-y Hilgendorf, 2007, Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines, Drug Metab. Dispos., 35, 1333, 10.1124/dmd.107.014902 Balakrishnan, 2005, Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT), Pharm. Res., 22, 1269, 10.1007/s11095-005-5274-8 Balakrishnan, 2006, Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target, Mol. Pharm., 3, 223, 10.1021/mp060022d Balimane, 2007, Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK–hPepT1 cells to Caco-2 cells, Arch. Pharm. Res., 30, 507, 10.1007/BF02980227 Satoh, 2005, Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B, Drug Metab. Dispos., 33, 518, 10.1124/dmd.104.002337 Matsushima, 2005, Identification of the hepatic efflux transporters of organic anions using double-transfected Madin–Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein, J. Pharmacol. Exp. Ther., 314, 1059, 10.1124/jpet.105.085589 Sasaki, 2002, Transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2), J. Biol. Chem., 277, 6497, 10.1074/jbc.M109081200 Letschert, 2005, Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2, J. Pharmacol. Exp. Ther., 313, 549, 10.1124/jpet.104.081224 Mita, 2006, Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs, Drug Metab. Dispos., 34, 1575, 10.1124/dmd.105.008748 Tolle-Sander, 2003, Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate, Pharm. Res., 20, 757, 10.1023/A:1023433502647 Cummins, 2002, Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4, J. Pharmacol. Exp. Ther., 300, 1036, 10.1124/jpet.300.3.1036 Cummins, 2003, In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model, J. Pharmacol. Exp. Ther., 305, 306, 10.1124/jpet.102.044719 Cummins, 2004, CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam, J. Pharmacol. Exp. Ther., 308, 143, 10.1124/jpet.103.058065 Chang, 2005, Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells, Mol. Pharm., 2, 428, 10.1021/mp050018m Lau, 2007, Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers, Clin. Pharmacol. Ther., 81, 194, 10.1038/sj.clpt.6100038 Gupta, 1990, Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration, J. Clin. Pharmacol., 30, 643, 10.1002/j.1552-4604.1990.tb01868.x 2007, 2149 Klein, 2004, Media to simulate the postprandial stomach I. Matching the physiochemical characteristics of standard breakfasts, J. Pharm. Pharmacol., 56, 605, 10.1211/0022357023367 Lui, 1986, Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans, J. Pharm. Sci., 75, 271, 10.1002/jps.2600750313 Charman, 1997, Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH, J. Pharm. Sci., 86, 269, 10.1021/js960085v Tso, 1994, Intestinal lipid absorption, 1867 Konishi, 2004, Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells, Br. J. Pharmacol., 143, 379, 10.1038/sj.bjp.0705804 Konishi, 2004, A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: monoglyceride as an active compound, Biofactors, 22, 71, 10.1002/biof.5520220113 Ingels, 2002, Simulated intestinal fluid as transport medium in the Caco-2 cell culture model, Int. J. Pharm., 232, 183, 10.1016/S0378-5173(01)00897-3 Balakrishnan, 2006, Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target, Mol. Pharm., 3, 223, 10.1021/mp060022d Benet, 2004, Unmasking the dynamic interplay between efflux transporters and metabolic enzymes, Int. J. Pharm., 277, 3, 10.1016/j.ijpharm.2002.12.002 Benet, 2003, Transporter–enzyme interactions: implications for predicting drug–drug interactions from in vitro data, Curr. Drug Metab., 4, 393, 10.2174/1389200033489389 Dresser, 2002, Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine, Clin. Pharmacol. Ther., 71, 11, 10.1067/mcp.2002.121152 Lavelle, 1996, Effect of food on the relative bioavailability of oral ganciclovir, J. Clin. Pharmacol., 36, 238, 10.1002/j.1552-4604.1996.tb04193.x Singh, 2005, A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate-release formulations, Drug Dev. Res., 65, 55, 10.1002/ddr.20008 Gu, 2007, Predicting effect of food on extent of drug absorption based on physicochemical properties, Pharm. Res., 24, 1118, 10.1007/s11095-007-9236-1 Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods., 44, 235, 10.1016/S1056-8719(00)00107-6 Lipinski, 2001, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug. Deliv. Rev., 46, 3, 10.1016/S0169-409X(00)00129-0 Azarmi, 2007, Current perspectives in dissolution testing of conventional and novel dosage forms, Int. J. Pharm., 28, 12, 10.1016/j.ijpharm.2006.10.001 Al-Behaisi, 2002, In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers, Eur. J. Pharm. Sci., 15, 157, 10.1016/S0928-0987(01)00195-6 Bailey, 1989, Ethanol enhances the hemodynamic effects of felodipine, Clin. Invest. Med., 12, 357 Dresser, 2003, The effects of fruit juices on drug disposition: a new model for drug interactions, Eur. J. Clin. Invest., 33, 10, 10.1046/j.1365-2362.33.s2.2.x Dresser, 2005, Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides, Clin. Pharmacol. Ther., 77, 170, 10.1016/j.clpt.2004.10.005 Petri, 2004, Transport characteristics of fexofenadine in the Caco-2 cell model, Pharm. Res., 21, 1398, 10.1023/B:PHAM.0000036913.90332.b1 Kamath, 2005, Effect of fruit juices on the oral bioavailability of fexofenadine in rats, J. Pharm. Sci., 94, 233, 10.1002/jps.20231 Parker, 2003, Effects of grapefruit juice on intestinal P-glycoprotein evaluation using digoxin in humans, Pharmacotherapy, 23, 979, 10.1592/phco.23.8.979.32881 Schwarz, 2005, Grapefruit juice ingestion significantly reduces talinolol bioavailability, Clin. Pharmacol. Ther., 77, 291, 10.1016/j.clpt.2004.11.111 Anuchapreeda, 2002, Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells, Biochem. Pharmacol., 64, 573, 10.1016/S0006-2952(02)01224-8 Zhang, 2003, Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport, J. Pharmacol. Exp. Ther., 304, 1258, 10.1124/jpet.102.044412 Kitagawa, 2004, Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells, J. Pharm. Pharmacol., 56, 1001, 10.1211/0022357044003 Barthomeuf, 2005, Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin, Cancer Chemother. Pharmacol., 56, 173, 10.1007/s00280-004-0914-y Kitagawa, 2005, Effects of alkyl gallates on P-glycoprotein function, Biochem. Pharmacol., 70, 1262, 10.1016/j.bcp.2005.07.013 Fuchikami, 2006, Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B, Drug Metab. Dispos., 34, 577, 10.1124/dmd.105.007872 Tseng, 2002, Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine, Pharm. Res., 1509, 10.1023/A:1020460700877 Wu, 2005, Modulatory effects of plant phenols on human multidrug resistance proteins 1, 4, and 5 (ABCC1, 4 and 5), FEBS J., 272, 4725, 10.1111/j.1742-4658.2005.04888.x Brocks, 2002, The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins, J. Pharm. Sci., 91, 1817, 10.1002/jps.10182 Humberstone, 1998, Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state, J. Pharm. Sci., 87, 936, 10.1021/js9704846 Persson, 2006, A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine, Pharm. Res., 23, 742, 10.1007/s11095-006-9607-z Humberstone, 1997, Lipid-based vehicles for the oral delivery of poorly water soluble drugs, Adv. Drug Deliv. Rev., 25, 103, 10.1016/S0169-409X(96)00494-2 Gershkovich, 2007, The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins, Int. J. Pharm., 333, 1, 10.1016/j.ijpharm.2007.01.012 Gershkovich, 2007, Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins, Eur. J. Pharm. Sci., 32, 24, 10.1016/j.ejps.2007.05.109 Porter, 2007, Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs, Nat. Rev. Drug Discov., 6, 231, 10.1038/nrd2197 Mueller, 1994, Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation, Pharm. Res., 11, 151, 10.1023/A:1018922517162 Mueller, 1994, Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine, Transplant. Proc., 26, 2957 Kaukonen, 2004, Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids, Pharm. Res., 21, 254, 10.1023/B:PHAM.0000016283.87709.a9 Carey, 1983, Lipid digestion and absorption, Annu. Rev. Physiol., 45, 651, 10.1146/annurev.ph.45.030183.003251 Kossena, 2004, Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach, J. Pharm. Sci., 93, 332, 10.1002/jps.10554 Kossena, 2005, Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug, J. Pharm. Sci., 94, 481, 10.1002/jps.20260 Subramanian, 2003, Effect of lipid excipients on in vitro pancreatic lipase activity, Drug Dev. Ind. Pharm., 29, 885, 10.1081/DDC-120024184 Risovic, 2004, Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B, Drug. Dev. Ind. Pharm., 30, 767, 10.1081/DDC-120039793 Wasan, 2006, Potential mechanisms by which lipid excipients increase the oral gastrointestinal absorption of drugs: a case study using amphotericin B, Bull. Tech. Gattefossé, 31 Ingels, 2003, Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2, J. Pharm. Sci., 92, 1545, 10.1002/jps.10408